Production of novel peptide‐targeting antibodies for anti‐Müllerian hormone receptor 2 and induction of cytotoxicity in ovarian cancer cells

• Published in: Scandinavian journal of immunology Vol. 101; no. 1; pp. e13426 - n/a
• Main Authors: Şakalar, Çağrı, Kurt, Büşra, Sezen, Sedat, Kaya, Savaş
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2025
• Subjects: Animals; Antibodies, Monoclonal - immunology; anti‐Müllerian hormone receptor type 2; Cell Line, Tumor; complement‐dependent cytotoxicity; Cytotoxicity; Enzyme-Linked Immunosorbent Assay; Fc receptors; Female; Humans; Immunoglobulin G; Immunotherapy; Mice; Monoclonal antibodies; Ovarian cancer; Ovarian Neoplasms - immunology; Ovarian Neoplasms - metabolism; peptide targets; Peptides; Peptides - immunology; Physicochemical properties; Receptors, Peptide - immunology; Receptors, Peptide - metabolism; Receptors, Transforming Growth Factor beta - immunology; peptide targets; anti‐Müllerian hormone receptor type 2; complement‐dependent cytotoxicity; ovarian cancer; monoclonal antibodies

Ovarian cancer is generally diagnosed at late stages. Monoclonal antibodies (MAbs) targeting antigens in ovarian cancer are used in the clinic. Anti‐Müllerian hormone receptor type 2 (AMHR2) is a receptor highly expressed in ovarian cancer and it is a potential target antigen for immunotherapy. Extr...